CAR T

Mar 14, 2025

The success of CAR-T therapies like Bristol-Myers Squibb/Bluebird bio’s ABECMA and Janssen’s CARVYKTI is reshaping treatment paradigms, challenging traditional options like stem cell transplants and proteasome inhibitors. The multiple myeloma market size in the US is responding rapidly from ~USD 15 billion, with in...

Feb 10, 2025

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer that originates in the bone marrow—the soft, inner part of bones where blood cells are produced—and swiftly moves into the blood. Globally, the burden of AML has been increasing over the past few decades. The exact cause of AML remains elusive, but severa...

Feb 07, 2025

Acute Myeloid Leukemia (AML) is a fast-moving and aggressive cancer that demands timely and effective treatment. With the current acute myeloid leukemia therapies showing limited success for many patients, the focus has shifted to breakthrough AML drugs that are redefining the treatment landscape. From innovative s...

Jul 24, 2024

Multiple myeloma is the second most prevalent blood cancer diagnosis in the United States, after non-Hodgkin lymphoma. Males are significantly more likely than females to have multiple myeloma. Myeloma incidence is strongly correlated with age, with the highest rates of diagnosis occurring in adults aged 65 years a...

Jan 01, 2024

T-cell receptor (TCR)-dependent treatment involves modified immune cells aimed at attacking particular tumor indicators. This treatment approach necessitates a systematic procedure including patient evaluation (e.g., for HLA-A*02:01 and precise tumor markers), collecting immune cells, creating the altered TCR produ...